Hypha’s newsletter for Q2 focusses on aspects of the metabolism of the experimental anti-cancer drug tivantinib. Tivantinib is extensively metabolised in… read more →

This quarter we illustrate a case study describing the successful provision of hundreds of milligrams of a major hydroxylated metabolite… read more →

Our new brochure on drug metabolites and C-H activated derivatives is now available. Inside we feature interesting case studies and client projects, including… read more →

Our newsletter for Q4 2016 features case studies illustrating the creation of sulfated metabolites and, in some cases, co-production of other conjugates.… read more →

Hypha will present a poster titled: Scaled-up production of human glucuronidated, oxidative and gut metabolites of Epacadostat, an investigational new… read more →

Hot-off-the-press news describing the scale-up of human metabolites resulting from mixed metabolism of Incyte’s first-in-class IDO1 inhibitor epacadostat (EPA) is… read more →

Scientists at Lilly presented a poster at ISSX 2015 summarising results of an evaluation of Hypha’s drug metabolite screening panels. In it… read more →

Dr Steve Wrigley will be talking at the forthcoming RSC conference “Bioactive Natural Products: Translating Promise into Practice” to be… read more →

Interested in drug metabolite formation and whether they would make better drug candidates? Want to maximize opportunities for late stage… read more →

Hypha will exhibit at the 27th Symposium on Medicinal Chemistry in Eastern England. Meet Julia and Frank in Hatfield on… read more →